---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-09-30T05:14:07.988358'
end_time: '2026-09-30T05:29:49.051183'
duration_seconds: 941.06
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: DLL1
  gene_symbol: DLL1
  uniprot_accession: O00548
  protein_description: 'RecName: Full=Delta-like protein 1 {ECO:0000305}; AltName:
    Full=Drosophila Delta homolog 1; Short=Delta1; Short=H-Delta-1; Flags: Precursor;'
  gene_info: Name=DLL1 {ECO:0000312|HGNC:HGNC:2908}; ORFNames=UNQ146/PRO172;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: DSL. (IPR001774); EGF. (IPR000742); EGF-like_Ca-bd_dom. (IPR001881);
    EGF-type_Asp/Asn_hydroxyl_site. (IPR000152); EGF_Ca-bd_CS. (IPR018097)
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 42
artifact_count: 2
artifact_sources:
  edison_answer_artifacts: 2
artifacts:
- filename: artifact-00.md
  path: DLL1-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
- filename: artifact-01.md
  path: DLL1-deep-research-falcon_artifacts/artifact-01.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-01
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O00548
- **Protein Description:** RecName: Full=Delta-like protein 1 {ECO:0000305}; AltName: Full=Drosophila Delta homolog 1; Short=Delta1; Short=H-Delta-1; Flags: Precursor;
- **Gene Information:** Name=DLL1 {ECO:0000312|HGNC:HGNC:2908}; ORFNames=UNQ146/PRO172;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** DSL. (IPR001774); EGF. (IPR000742); EGF-like_Ca-bd_dom. (IPR001881); EGF-type_Asp/Asn_hydroxyl_site. (IPR000152); EGF_Ca-bd_CS. (IPR018097)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "DLL1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'DLL1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **DLL1** (gene ID: DLL1, UniProt: O00548) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** O00548
- **Protein Description:** RecName: Full=Delta-like protein 1 {ECO:0000305}; AltName: Full=Drosophila Delta homolog 1; Short=Delta1; Short=H-Delta-1; Flags: Precursor;
- **Gene Information:** Name=DLL1 {ECO:0000312|HGNC:HGNC:2908}; ORFNames=UNQ146/PRO172;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** DSL. (IPR001774); EGF. (IPR000742); EGF-like_Ca-bd_dom. (IPR001881); EGF-type_Asp/Asn_hydroxyl_site. (IPR000152); EGF_Ca-bd_CS. (IPR018097)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "DLL1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'DLL1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **DLL1** (gene ID: DLL1, UniProt: O00548) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

# Comprehensive Research Report: DLL1 (Delta-like Protein 1)

## Gene Identity Verification

The research target, DLL1 (UniProt O00548), encodes Delta-like protein 1, also known as Drosophila Delta homolog 1 (Delta1 or H-Delta-1), in Homo sapiens (sen2023theintricatenotch pages 2-4). The protein is a member of the canonical Delta/Serrate/LAG-2 (DSL) family of Notch ligands and contains the characteristic DSL domain, multiple EGF-like repeats, and calcium-binding EGF domains specified in the UniProt annotation (sen2023theintricatenotch pages 2-4, hirano2020deltalike1and pages 1-2). This identity has been confirmed across multiple recent publications from 2023–2024 (sen2023theintricatenotch pages 2-4, stojanovic2024tolllikereceptorsas pages 1-2).

## Primary Molecular Function

### Structural Organization and Receptor Binding

DLL1 is a type I single-pass transmembrane protein that functions as a canonical Notch ligand (sen2023theintricatenotch pages 2-4, hirano2020deltalike1and pages 1-2). Its extracellular region comprises an N-terminal MNNL (module at the N-terminus of Notch ligands) domain, the conserved DSL domain, and eight EGF-like repeats (hirano2020deltalike1and pages 1-2, hirano2020deltalike1and pages 3-4). Unlike the closely related ligand DLL4, DLL1 contains a DOS (Delta and OSM-11-like proteins) motif within its first two EGF repeats, which contributes to its distinctive receptor-binding mechanism (hirano2020deltalike1and pages 3-4, hirano2020deltalike1and pages 7-8). The intracellular domain includes a C-terminal PDZ-binding motif that mediates interactions with scaffolding proteins (sen2023theintricatenotch pages 2-4, vazquezulloa2022reversibleandbidirectional pages 8-11).

DLL1 activates Notch signaling through a DSL-plus-DOS interaction strategy, contrasting with DLL4's DSL-plus-MNNL mechanism (hirano2020deltalike1and pages 7-8, hirano2020deltalike1and pages 8-9). The MNNL domain of DLL1 contains proline-rich sequences that restrict loop flexibility, contributing to differences in receptor affinity and signaling potency compared to DLL4 (hirano2020deltalike1and pages 6-7, hirano2020deltalike1and pages 8-9). Functional studies demonstrate that DLL1 engages and activates NOTCH1 and NOTCH2 receptors, though evidence for NOTCH3 and NOTCH4 activation is less definitive (hirano2022dll1canfunction pages 4-6, hirano2020deltalike1and pages 9-11, hirano2020deltalike1and pages 6-7, hirano2020deltalike1and pages 1-2).

### Mechanism of Notch Activation

DLL1 functions as a membrane-tethered juxtacrine signal that activates Notch receptors on adjacent cells through a force-dependent mechanism (sen2023theintricatenotch pages 2-4, stojanovic2024tolllikereceptorsas pages 1-2). When DLL1 on a sender cell binds a Notch receptor on a neighboring receiver cell, the ligand undergoes endocytosis in the sender cell, generating mechanical tension across the ligand–receptor complex (stojanovic2024tolllikereceptorsas pages 1-2, vazquezulloa2022reversibleandbidirectional pages 11-13). This pulling force removes or destabilizes the Notch extracellular domain (NECD), exposing proteolytic cleavage sites (stojanovic2024tolllikereceptorsas pages 1-2). 

ADAM metalloproteases (ADAM10 or ADAM17) perform S2 cleavage, followed by γ-secretase-mediated S3 cleavage, which releases the Notch intracellular domain (NICD) (sen2023theintricatenotch pages 2-4, stojanovic2024tolllikereceptorsas pages 1-2). NICD translocates to the nucleus, where it forms a transcriptional activation complex with CSL/RBPJ (recombination signal binding protein for immunoglobulin kappa J region) and MAML (mastermind-like) proteins, displacing corepressors and activating Notch target genes (sen2023theintricatenotch pages 2-4, hirano2022dll1canfunction pages 1-2, kulkarni2024noncanonicalnongenomicmorphogen pages 3-5).

## Subcellular Localization

DLL1 is primarily localized to the plasma membrane of signal-sending cells, where it mediates contact-dependent trans-signaling with Notch receptors on adjacent cells (stojanovic2024tolllikereceptorsas pages 1-2, hirano2020deltalike1and pages 1-2, nian2022evolvingrolesof pages 7-9). The protein is enriched at adherens junctions through interactions with PDZ-domain scaffolding proteins including MAGI, MPDZ/MUPP1, and syntenin, which recruit, stabilize, and retain DLL1 at cell-contact sites (vazquezulloa2022reversibleandbidirectional pages 15-16). This spatial concentration increases the probability of productive receptor engagement during juxtacrine signaling (vazquezulloa2022reversibleandbidirectional pages 15-16).

Polarized endocytic recycling mediated by Rab11-dependent pathways can control DLL1 distribution between apical and basolateral membrane domains, while Sec15-positive exocyst vesicles participate in targeted delivery (vazquezulloa2022reversibleandbidirectional pages 11-13). DLL1 can also undergo regulated intramembrane proteolysis, generating soluble extracellular fragments and an intracellular domain (DLL1ICD) that may translocate to the nucleus or remain cytoplasmic, participating in reverse or bidirectional signaling (vazquezulloa2022reversibleandbidirectional pages 13-14, vazquezulloa2022reversibleandbidirectional pages 8-11, vazquezulloa2022reversibleandbidirectional pages 11-13).

## Post-Translational Regulation

### Ubiquitination and Endocytosis

E3 ubiquitin ligases of the Neuralized and Mind-bomb (MIB) families modify the DLL1 intracellular domain, promoting epsin-dependent endocytosis (sen2023theintricatenotch pages 2-4, vazquezulloa2022reversibleandbidirectional pages 11-13). This ubiquitination is essential for converting surface DLL1 into a signaling-competent ligand capable of generating the mechanical force required for Notch activation (vazquezulloa2022reversibleandbidirectional pages 11-13, vazquezulloa2022reversibleandbidirectional pages 5-7). Only ligands that can activate Notch undergo monoubiquitination and internalization into specific recycling compartments (vazquezulloa2022reversibleandbidirectional pages 11-13). Rab11-dependent recycling returns active ligand to the plasma membrane, ensuring sustained signaling capacity (vazquezulloa2022reversibleandbidirectional pages 11-13).

### Proteolytic Processing

DLL1 undergoes ectodomain shedding by ADAM proteases (ADAM9, ADAM10, ADAM12, or ADAM17), releasing soluble DLL1 fragments into the extracellular milieu (vazquezulloa2022reversibleandbidirectional pages 11-13). The remaining membrane-tethered C-terminal fragment is subsequently cleaved by γ-secretase in a transmembrane-valine-dependent manner, releasing DLL1ICD (vazquezulloa2022reversibleandbidirectional pages 11-13). These processing events can modulate signaling: soluble ectodomains may compete with membrane-bound ligand or exert context-dependent effects, while DLL1ICD can interact with transcriptional regulators including SMAD2/3/4, NICD, and JUN/JUNB in the sender cell (vazquezulloa2022reversibleandbidirectional pages 13-14).

### Additional Modifications

Mouse DLL1 is phosphorylated at serine 693 when associated with the plasma membrane, providing an additional regulatory control point (vazquezulloa2022reversibleandbidirectional pages 15-16). Membrane stability is further regulated by SYNJBP2/ARIP2, which increases DLL1 half-life by blocking lysosomal degradation (vazquezulloa2022reversibleandbidirectional pages 15-16). Fringe-family glycosyltransferases modify Notch receptors (not DLL1 itself) by adding N-acetylglucosamine to O-fucose residues on receptor EGF repeats, thereby increasing receptor responsiveness to Delta-family ligands including DLL1 (hirano2020deltalike1and pages 3-4, vazquezulloa2022reversibleandbidirectional pages 5-7).

## Signaling Pathways and Downstream Targets

### Canonical Notch Target Genes

DLL1-mediated Notch activation induces transcription of canonical target genes in receiver cells. The primary targets are HES (hairy and enhancer of split) and HEY (hairy/enhancer of split related with YRPW motif) family genes, which encode basic helix-loop-helix transcriptional repressors that mediate lateral inhibition and regulate cell-fate decisions (stojanovic2024tolllikereceptorsas pages 1-2, katoh2020precisionmedicinefor pages 1-2, mcintyre2020overviewofbasic pages 25-27). Additional context-dependent targets include BMI1 (polycomb complex protein), CCND1 (cyclin D1), CD44, CDKN1A/p21, MYC, NOTCH3, REST (RE1-silencing transcription factor), and TCF7 (transcription factor 7), which collectively regulate cell-cycle progression, progenitor maintenance, and lineage identity (katoh2020precisionmedicinefor pages 1-2).

### Reverse Signaling

Cleaved DLL1ICD can function in the sender cell through non-canonical mechanisms. DLL1ICD binds NICD and interferes with NICD–RBPJ–MAML complex assembly, providing negative feedback regulation of Notch signaling (vazquezulloa2022reversibleandbidirectional pages 13-14). DLL1ICD also interacts with SMAD2, SMAD3, and SMAD4, modulating TGF-β/SMAD-dependent transcription, and inhibits DNA binding by JUN and JUNB, affecting AP-1 activity (vazquezulloa2022reversibleandbidirectional pages 13-14). In certain contexts, DLL1ICD expression increases p21 levels and induces proliferation arrest (vazquezulloa2022reversibleandbidirectional pages 13-14).

## Biological Functions

### Somitogenesis and the Segmentation Clock

DLL1 plays a central role in vertebrate somitogenesis by functioning as an oscillating Notch ligand within the segmentation clock (miao2024cellularandmolecular pages 4-6, ramesh2024speciesspecificrolesof pages 13-14, anderson2020fgf4iscritical pages 1-5). In the presomitic mesoderm (PSM), DLL1 expression oscillates in coordination with Notch1 receptor and NICD, synchronizing autonomous cellular oscillators into coordinated posterior-to-anterior traveling waves (miao2024cellularandmolecular pages 4-6, anderson2020fgf4iscritical pages 1-5). Optogenetic manipulation demonstrated that DLL1 can directly entrain HES1 oscillations, confirming its active role in timing coordination rather than merely marking clock activity (miao2024cellularandmolecular pages 4-6).

Mouse Dll1-null embryos exhibit severe segmentation defects: they lose nearly all Hes7 expression except in the caudal PSM, completely abolish Lfng (lunatic fringe) expression, fail to establish normal rostrocaudal compartmentalization, and cannot form epithelial somites, leading to incomplete axis development and embryonic lethality (ramesh2024speciesspecificrolesof pages 13-14, ramesh2024speciesspecificrolesof pages 14-16). Critically, overexpression or non-oscillatory DLL1 also disrupts somitogenesis, demonstrating that the temporal dynamics of DLL1 expression—not merely its abundance—are functionally essential (ramesh2024speciesspecificrolesof pages 14-16). Recent work (2024) confirms DLL1 as a core regulator whose loss disrupts all examined HES genes and prevents normal segmentation-clock function (ramesh2024speciesspecificrolesof pages 13-14).

### Muscle Stem Cell Maintenance and Regeneration

In adult muscle, DLL1 regulates the balance between satellite cell maintenance and myogenic differentiation through oscillatory lateral-inhibition signaling (zhang2021oscillationsofdeltalike1 pages 4-5, zhang2021oscillationsofdeltalike1 pages 1-2). Following muscle injury, activated satellite cells and myogenic progenitors express DLL1 in an oscillatory pattern with an approximately 2–3 hour period (zhang2021oscillationsofdeltalike1 pages 4-5, zhang2021oscillationsofdeltalike1 pages 1-2). DLL1 oscillations are controlled by a regulatory network involving HES1 (oscillatory pacemaker) and MYOD (enhances DLL1 expression and maintains robust levels) (zhang2021oscillationsofdeltalike1 pages 1-2).

DLL1 on differentiating cells activates Notch in neighboring progenitors, inhibiting their premature differentiation and preserving the self-renewing stem-cell pool (sachan2023notchsignallingmultifaceted pages 14-14, zhang2021oscillationsofdeltalike1 pages 1-2). Genetic disruption of DLL1 oscillations while maintaining normal average expression levels causes premature differentiation, reduces PAX7-positive stem cells, increases MYOG-positive differentiating cells, and severely impairs muscle regeneration (zhang2021oscillationsofdeltalike1 pages 4-5, zhang2021oscillationsofdeltalike1 pages 3-4). Regenerated myofibers in Dll1-deficient muscle display fewer nuclei and markedly reduced diameter, demonstrating the functional importance of DLL1 dynamics for effective tissue repair (zhang2021oscillationsofdeltalike1 pages 4-5).

### T-Cell Development and Hematopoietic Lineage Decisions

In the thymic epithelium, DLL1 can function as a Notch ligand that activates NOTCH1 and NOTCH2 on hematopoietic progenitors, inducing T-cell lineage specification (hirano2022dll1canfunction pages 4-6, hirano2022dll1canfunction pages 1-2). Conditional expression of DLL1 in thymic epithelial cells completely rescued the T-cell developmental defect caused by Dll4 deletion, demonstrating functional sufficiency (hirano2022dll1canfunction pages 1-2). However, DLL4 is the physiologically dominant ligand in the mammalian thymus and is typically more potent in T-lineage induction assays (hirano2020deltalike1and pages 1-2).

In hematopoietic lineage decisions, DLL1-mediated Notch signaling suppresses B-cell development while promoting T-lineage differentiation (hirano2020deltalike1and pages 2-3, hirano2020deltalike1and pages 6-7). DLL1 is also required for maintaining marginal-zone B cells in normal mice, indicating context-dependent functions in hematopoietic tissue homeostasis (hirano2020deltalike1and pages 17-18). DLL1 signals through both NOTCH1 and NOTCH2 in hematopoietic progenitors, whereas DLL4 acts predominantly through NOTCH1 in the tested systems (hirano2020deltalike1and pages 9-11).

## Disease Associations and Clinical Relevance

### Developmental Disorders

**Spondylocostal Dysostosis Type 7 (SCDO7):** A homozygous DLL1 missense variant, c.1534G>A (p.Gly512Arg), causes autosomal-recessive spondylocostal dysostosis characterized by scoliosis, multiple vertebral deformities, and fusion of thoracic vertebrae including T4–T5, T6–T8, and T11–T12 (umair2022clinicalgeneticsof pages 7-8, umair2022clinicalgeneticsof pages 2-3, umair2022clinicalgeneticsof pages 3-4). This rare disorder results from disrupted Notch segmentation-clock function during embryonic somite formation (umair2022clinicalgeneticsof pages 8-10, umair2022clinicalgeneticsof pages 2-3). As of a 2022 review, only one DLL1 variant had been specifically linked to vertebral malformations, making SCDO7 an uncommon but biologically compelling disease entity (umair2022clinicalgeneticsof pages 7-8).

**Neurodevelopmental Disorders:** Heterozygous DLL1 loss-of-function variants are associated with variable neurodevelopmental phenotypes including developmental delay, cortical dysplasia, cerebellar hypoplasia, hypotonia, ataxia, autistic features, hearing loss, congenital heart disease, and cleft lip/palate (umair2022clinicalgeneticsof pages 5-7, umair2022clinicalgeneticsof pages 7-8, umair2022clinicalgeneticsof pages 2-3). Skeletal manifestations such as kyphosis, scoliosis, and joint hyperlaxity may accompany these conditions (umair2022clinicalgeneticsof pages 7-8). The phenotypic spectrum reflects DLL1's broad developmental roles, though genotype–phenotype correlations remain incompletely characterized (umair2022clinicalgeneticsof pages 5-7).

### Cancer Biology

DLL1's role in cancer is highly context-dependent (you2023targetingthedllnotch pages 4-5, you2023targetingthedllnotch pages 8-9). In glioma, DLL1 participates with NOTCH1 and JAGGED1 in signaling critical for tumor-cell survival and proliferation, suggesting a tumor-promoting function (you2023targetingthedllnotch pages 8-9). Estrogen-dependent DLL1-mediated Notch signaling has been identified in luminal breast cancer (you2023targetingthedllnotch pages 8-8). Conversely, in osteosarcoma, DLL1 downregulation mediated by miR-34a-5p is associated with multidrug chemoresistance, suggesting that loss of DLL1 may contribute to treatment failure (you2023targetingthedllnotch pages 8-9). These findings indicate that DLL1/Notch signaling may have tumor-suppressive effects in certain contexts, including pancreatic carcinoma and lung cancer (you2023targetingthedllnotch pages 4-5).

**Therapeutic Applications:** Engineered multivalent DLL1 molecules have shown promise in preclinical lung-cancer models, where they enhanced antitumor T-cell immunity and improved the efficacy of EGFR-targeted therapy (you2023targetingthedllnotch pages 8-9). This suggests potential immunotherapeutic applications exploiting DLL1-mediated Notch activation. The DLL/Notch pathway more broadly is implicated in cancer stemness and tumor angiogenesis, making it a target for therapeutic intervention (you2023targetingthedllnotch pages 1-1, you2023targetingthedllnotch pages 2-3).

### Biomarker in Sepsis

Soluble DLL1 has emerged as a potential diagnostic biomarker for sepsis. In a 2023 secondary analysis of 405 patients with inflammatory or infectious diseases, soluble DLL1 distinguished sepsis from uncomplicated infections and sterile inflammation with an area under the receiver operating characteristic curve (AUROC) of 0.823 (95% CI 0.731–0.914), outperforming C-reactive protein (0.758), procalcitonin (0.593), and white blood cell count (0.577) (vazquezulloa2022reversibleandbidirectional pages 13-14). Bacterial infection upregulates DLL1 on primary human monocytes, and elevated circulating DLL1 may reflect infection-driven immune activation (vazquezulloa2022reversibleandbidirectional pages 13-14). External prospective validation is required before clinical implementation.

## Summary Tables

Two comprehensive tables synthesize the molecular, cellular, and clinical aspects of DLL1 function:

| Feature class | DLL1 feature | Functional significance and evidence | Key qualifications | Citations |
|---|---|---|---|---|
| Identity and topology | Human DLL1 is a canonical Delta/Serrate/LAG-2-family Notch ligand and type-I single-pass transmembrane protein. | An extracellular receptor-binding region faces the extracellular space; one transmembrane helix anchors DLL1 at the cell surface; a short cytoplasmic tail controls trafficking, endocytosis, and intracellular interactions. DLL1 therefore functions primarily as a membrane-tethered juxtacrine signal rather than as an enzyme or conventional soluble ligand. | This identity corresponds to human DLL1/Delta-like protein 1, not the similarly named non-canonical ligand **DLK1** or the distinct ligands DLL3 and DLL4. | (sen2023theintricatenotch pages 2-4, hirano2020deltalike1and pages 1-2, vazquezulloa2022reversibleandbidirectional pages 8-11) |
| Extracellular structure | N-terminal MNNL/C2-like domain | Contributes to ligand architecture and productive Notch engagement. DLL1 has a relatively rigid, proline-containing MNNL loop compared with DLL4, helping explain ligand-specific differences in receptor affinity and signaling potency. | The MNNL domain contributes in concert with adjacent domains; it is not the sole DLL1 receptor-binding determinant. | (hirano2020deltalike1and pages 1-2, hirano2020deltalike1and pages 7-8, hirano2020deltalike1and pages 6-7) |
| Extracellular structure | DSL domain | The conserved Delta/Serrate/LAG-2 domain is the defining canonical Notch-ligand module and forms a central part of the receptor-interaction surface required for trans-activation. | Productive signaling depends on the domain’s structural context and cooperation with neighboring EGF repeats. | (sen2023theintricatenotch pages 2-4, hirano2020deltalike1and pages 3-4, hirano2020deltalike1and pages 11-13) |
| Extracellular structure | Eight EGF-like repeats, including calcium-binding EGF motifs | EGF repeats stabilize the elongated extracellular region and contribute to receptor recognition. The first two repeats cooperate especially closely with the DSL domain during DLL1-mediated Notch engagement. | These features align with the DSL, EGF, calcium-binding EGF, and EGF hydroxylation-site annotations reported for UniProt O00548. | (hirano2020deltalike1and pages 1-2, hirano2020deltalike1and pages 3-4) |
| Extracellular structure | DOS motif in EGF repeats 1–2 | The Delta-and-OSM-11-like-proteins motif provides an auxiliary receptor-binding interface. DLL1 principally uses a **DSL-plus-DOS** interaction mode, contrasting with the stronger MNNL contribution reported for DLL4. | Domain-swapping evidence is largely derived from mouse proteins and cell-based assays; exact contributions may depend on receptor glycosylation and cellular context. | (hirano2020deltalike1and pages 3-4, hirano2020deltalike1and pages 7-8, hirano2020deltalike1and pages 8-9) |
| Intracellular structure | Cytoplasmic tail with a C-terminal PDZ-binding motif | Supports interactions with PDZ-domain scaffolds and trafficking proteins. MAGI proteins, MPDZ/MUPP1, syntenin, and related partners can recruit, stabilize, or retain DLL1 at adherens junctions and the plasma membrane, thereby affecting signaling competence. | The cytoplasmic tail does not catalyze the canonical receiver-cell response; it regulates ligand presentation and may also support reverse signaling. | (sen2023theintricatenotch pages 2-4, vazquezulloa2022reversibleandbidirectional pages 8-11, vazquezulloa2022reversibleandbidirectional pages 15-16) |
| Primary localization | Plasma membrane of the signal-sending cell | Cell-surface DLL1 binds Notch on an adjacent receiver cell, making its primary physiological mode **contact-dependent trans-signaling**. Ligand endocytosis supplies mechanical tension that helps expose the receptor’s protease-sensitive negative regulatory region. | DLL1 can also interact with Notch in the same cell, producing cis-regulation, but its principal activating role is trans-cellular. | (stojanovic2024tolllikereceptorsas pages 1-2, hirano2020deltalike1and pages 1-2, nian2022evolvingrolesof pages 7-9) |
| Specialized localization | Adherens junctions and polarized cell-contact domains | PDZ-scaffold interactions concentrate and stabilize DLL1 where neighboring cells contact one another, increasing the probability and spatial precision of productive receptor engagement. Polarized endocytic recycling can further control apical versus basolateral ligand delivery. | Localization is dynamic and tissue-dependent rather than restricted permanently to adherens junctions. | (vazquezulloa2022reversibleandbidirectional pages 15-16, vazquezulloa2022reversibleandbidirectional pages 11-13, vazquezulloa2022reversibleandbidirectional pages 5-7) |
| Processed-fragment localization | Extracellular milieu, cytoplasm, and potentially nucleus | Ectodomain shedding releases soluble DLL1 fragments; subsequent intramembrane cleavage releases a DLL1 intracellular domain that can remain cytoplasmic or enter the nucleus and interact with NICD, SMAD proteins, JUN/JUNB, and other regulators. | Reverse signaling by DLL1 fragments is supported experimentally but is less firmly established as a general physiological function than canonical cell-surface Notch activation. | (vazquezulloa2022reversibleandbidirectional pages 13-14, vazquezulloa2022reversibleandbidirectional pages 8-11, vazquezulloa2022reversibleandbidirectional pages 11-13) |
| Receptor specificity | NOTCH1 | DLL1 directly engages and activates NOTCH1. The DLL1 DSL domain and DOS-containing EGF1–2 region support productive binding; ligand-driven pulling permits ADAM S2 cleavage followed by γ-secretase cleavage and release of NOTCH1 intracellular domain. | Soluble-fragment assays reported approximately tenfold lower DLL1–NOTCH1 affinity than DLL4–NOTCH1 affinity; such measurements may not reproduce full-length membrane signaling. | (hirano2020deltalike1and pages 7-8, hirano2020deltalike1and pages 1-2) |
| Receptor specificity | NOTCH2 | Binding and functional studies support DLL1 engagement of NOTCH2. In thymic and hematopoietic models, DLL1 can signal through NOTCH1 and NOTCH2, whereas DLL4 is more strongly associated with NOTCH1 in the tested settings. | Receptor usage is context-dependent; evidence is strongest from mouse thymic and hematopoietic systems rather than a complete quantitative human receptor panel. | (hirano2022dll1canfunction pages 4-6, hirano2020deltalike1and pages 9-11, hirano2020deltalike1and pages 6-7) |
| Receptor specificity | NOTCH3 and NOTCH4 | Canonical pathway summaries sometimes treat DLL1 as capable of engaging multiple mammalian Notch paralogs, but the gathered direct evidence does not establish a definitive quantitative activation profile for NOTCH3 or NOTCH4. | Claims that DLL1 activates all four receptors should therefore be treated cautiously unless supported by receptor-specific experiments in the relevant cell type. | (hirano2022dll1canfunction pages 4-6, hirano2020deltalike1and pages 11-13) |
| Activation mechanism | Force-dependent canonical Notch activation | DLL1 binds Notch in trans and is internalized by the sender cell. Mechanical pulling destabilizes the receptor’s protective extracellular conformation, enabling ADAM10/17-family S2 cleavage and presenilin/γ-secretase S3 cleavage. Released NICD enters the nucleus and forms an activating complex with CSL/RBPJ and MAML. | DLL1 is a signaling ligand, not a protease: the receptor-cleavage reactions are performed by ADAM proteases and γ-secretase. | (sen2023theintricatenotch pages 2-4, stojanovic2024tolllikereceptorsas pages 1-2, hirano2020deltalike1and pages 11-13) |
| Post-translational regulation | Ubiquitination | E3 ubiquitin ligases of the Neuralized/Mind-bomb class modify the DLL1 cytoplasmic region, promoting epsin-dependent internalization and conversion of surface DLL1 into a signaling-competent ligand. | Ubiquitination regulates trafficking and mechanical activity rather than directly modifying the Notch receptor-binding surface. Exact DLL1 ubiquitination sites and mono- versus polyubiquitin functions remain incompletely resolved. | (sen2023theintricatenotch pages 2-4, vazquezulloa2022reversibleandbidirectional pages 11-13, hirano2020deltalike1and pages 17-18) |
| Post-translational regulation | Endocytosis, trans-endocytosis, and recycling | Internalization generates pulling force across the ligand–receptor complex and can internalize the bound Notch ectodomain into the sender cell. Epsin- and Rab11-dependent recycling returns active ligand to the plasma membrane, while exocyst-mediated polarized delivery helps position signaling-competent DLL1. | Endocytosis is integral to activation, not merely a route for ligand degradation. | (stojanovic2024tolllikereceptorsas pages 1-2, vazquezulloa2022reversibleandbidirectional pages 11-13, vazquezulloa2022reversibleandbidirectional pages 5-7) |
| Post-translational regulation | Phosphorylation | Mouse DLL1 is phosphorylated at Ser693 while associated with the plasma membrane; phosphorylation provides an additional potential control point for cytoplasmic-tail interactions and trafficking. | The physiological consequence and direct correspondence of this site in human DLL1 require cautious interpretation. | (vazquezulloa2022reversibleandbidirectional pages 15-16) |
| Post-translational regulation | Ectodomain shedding by ADAM proteases | ADAM9, ADAM10, ADAM12, or ADAM17 have been implicated in DLL1 ectodomain shedding, generating soluble extracellular DLL1 and a membrane-tethered C-terminal fragment. Soluble ectodomains may compete with membrane ligand or exert context-dependent signaling effects. | Soluble DLL1 does not automatically reproduce force-dependent activation by membrane-bound DLL1 and may instead inhibit signaling unless appropriately clustered or immobilized. | (vazquezulloa2022reversibleandbidirectional pages 11-13) |
| Post-translational regulation | γ-Secretase cleavage of DLL1 | After ectodomain shedding, γ-secretase cleaves the residual membrane fragment; cleavage depends on a transmembrane valine and releases DLL1 intracellular domain. | This is ligand processing and possible reverse signaling, distinct from γ-secretase cleavage of the Notch receptor that generates NICD. | (vazquezulloa2022reversibleandbidirectional pages 13-14, vazquezulloa2022reversibleandbidirectional pages 11-13) |
| Post-translational regulation | Membrane stabilization versus lysosomal degradation | SYNJBP2/ARIP2 can extend DLL1 half-life by limiting lysosomal degradation, while MAGI, MPDZ/MUPP1, and syntenin promote junctional recruitment or membrane retention. | These mechanisms tune ligand abundance and spatial presentation rather than receptor specificity alone. | (vazquezulloa2022reversibleandbidirectional pages 15-16) |
| Receptor-side modulation | Fringe-dependent Notch glycosylation | Lunatic and Manic Fringe modify O-fucose-bearing Notch EGF repeats, generally increasing receptor responsiveness to Delta-family ligands such as DLL1 while altering cis- and trans-interactions. | This is a post-translational modification of the receptor, not DLL1, but it materially determines DLL1–Notch signaling strength and specificity. | (hirano2020deltalike1and pages 3-4, vazquezulloa2022reversibleandbidirectional pages 5-7) |
| Direct nuclear signaling output | NICD–CSL/RBPJ–MAML transcriptional complex | DLL1-triggered receptor cleavage produces NICD, which enters the receiver-cell nucleus, displaces CSL-associated corepressors, recruits MAML and coactivators, and activates context-specific Notch-responsive transcription. | DLL1 itself does not normally enter the receiver-cell nucleus; NICD is the receptor-derived transcriptional effector. | (sen2023theintricatenotch pages 2-4, hirano2022dll1canfunction pages 1-2, kulkarni2024noncanonicalnongenomicmorphogen pages 3-5) |
| Core downstream targets | **HES1 and other HES-family genes** | HES genes encode basic helix–loop–helix transcriptional repressors that mediate lateral inhibition, suppress differentiation programs, and participate in oscillatory feedback. DLL1 stimulation can produce strong or pulsed HES1/NICD dynamics. | Target selection and response dynamics vary by receptor, ligand presentation, and cell type. | (stojanovic2024tolllikereceptorsas pages 1-2, katoh2020precisionmedicinefor pages 1-2, mcintyre2020overviewofbasic pages 25-27) |
| Core downstream targets | **HEY1, HEY2, and other HEY-family genes** | HEY transcriptional repressors are canonical Notch outputs involved in developmental cell-fate and patterning programs. DLL1-dependent signaling contributes to HEY expression in segmentation and other developmental contexts. | Individual ligand–receptor combinations may differ; for example, DLL1–NOTCH1 acts linearly in some Hey2-expression settings. | (katoh2020precisionmedicinefor pages 1-2, ramesh2024speciesspecificrolesof pages 13-14, you2023targetingthedllnotch pages 2-3) |
| Context-dependent downstream targets | **BMI1, CCND1, CD44, CDKN1A/p21, MYC, NOTCH3, REST, and TCF7** | These genes are established outputs of canonical NICD/CSL signaling in selected cellular contexts and connect Notch activation to progenitor maintenance, cell-cycle control, lineage identity, and oncogenic or tumor-suppressive behavior. | They should not be interpreted as universally induced, DLL1-exclusive direct targets; the available source describes context-dependent canonical Notch outputs rather than a DLL1-only transcriptional signature. | (katoh2020precisionmedicinefor pages 1-2) |
| Reverse-signaling outputs | MYOD, TGF-β/SMAD, AP-1, and p21-associated programs | Cleaved DLL1 intracellular domain can bind NICD and interfere with NICD–RBPJ–MAML assembly, interact with SMAD2/3/4, inhibit JUN/JUNB DNA binding, modulate MYOD-related programs, and increase p21 in experimental systems. | These proposed sender-cell outputs are less universally established than DLL1-driven canonical signaling in the adjacent receiver cell. | (vazquezulloa2022reversibleandbidirectional pages 13-14) |


*Table: This table integrates DLL1 domain architecture, localization, receptor usage, trafficking and proteolytic regulation, and downstream transcriptional outputs. It distinguishes well-supported canonical ligand activity from context-dependent receptor specificity and emerging reverse-signaling functions.*

| Biological process or clinical context | DLL1 mechanism | Key evidence or quantitative detail | Phenotypic or clinical outcome | Evidence scope |
|---|---|---|---|---|
| Somitogenesis and segmentation clock | Oscillatory DLL1 on presomitic-mesoderm cells activates Notch in neighboring cells, synchronizing autonomous cellular oscillators into posterior-to-anterior waves. The DLL1–Notch–HES/HER feedback system couples timing across the tissue; anterior arrest of oscillations permits NICD–TBX6-dependent **MESP2** activation and somite patterning. | Optogenetic DLL1 can entrain **HES1** oscillations. Mouse loss of *Dll1* nearly eliminates **Hes7**, abolishes **Lfng**, disrupts rostrocaudal compartmentalization, and prevents normal epithelial-somite formation. Excess or non-oscillatory DLL1 also disrupts somitogenesis, showing that dynamics—not merely abundance—matter. (miao2024cellularandmolecular pages 4-6, ramesh2024speciesspecificrolesof pages 13-14, ramesh2024speciesspecificrolesof pages 14-16, anderson2020fgf4iscritical pages 1-5) | Correctly timed signaling produces regularly spaced somites and the segmented vertebral axis; disrupted DLL1 dosage or dynamics causes defective segmentation, incomplete axial development, and embryonic lethality in severe mouse models. | Strong developmental evidence, principally from mouse embryos and experimental models; recent authoritative synthesis published in 2024. |
| Muscle stem-cell maintenance and regeneration | In activated satellite cells and myogenic progenitors, DLL1 oscillates under a **HES1–MYOD** regulatory network. DLL1 activates Notch in adjacent cells to inhibit premature differentiation while the sender cell can progress toward differentiation, creating dynamic lateral inhibition that preserves the stem/progenitor pool. | DLL1 oscillations have an approximately **2–3-hour period** and are often about half a cycle out of phase in contacting cells. Disrupting oscillations while retaining similar average DLL1 expression causes premature differentiation, showing that temporal pattern carries functional information. (zhang2021oscillationsofdeltalike1 pages 4-5, zhang2021oscillationsofdeltalike1 pages 1-2, zhang2021oscillationsofdeltalike1 pages 12-13) | Loss or mistiming of DLL1 reduces **PAX7-positive** stem cells, increases **MYOG-positive** differentiating cells, decreases self-renewal, and impairs repair, with fewer nuclei and reduced diameter in regenerated myofibres. (zhang2021oscillationsofdeltalike1 pages 4-5, zhang2021oscillationsofdeltalike1 pages 3-4) | Direct genetic, live-reporter, culture, and injury-regeneration evidence in mice; mechanistically strong but not yet a DLL1-directed human therapy. |
| T-cell development and thymic signaling | Epithelial DLL1 can activate **NOTCH1** and **NOTCH2** on hematopoietic progenitors, inducing the transcriptional program for T-lineage specification. Receptor activation releases NICD, which complexes with RBPJ/CSL and MAML in the nucleus. | In mice, thymic epithelial expression of DLL1 completely rescued the T-cell developmental defect caused by epithelial *Dll4* deletion. Bone-marrow chimera experiments showed signaling sufficient through NOTCH1 or NOTCH2, whereas DLL4 acted predominantly through NOTCH1 in that setting. (hirano2022dll1canfunction pages 4-6, hirano2022dll1canfunction pages 1-2) | DLL1 can support thymic cellularity and T-cell production when appropriately presented, although DLL4 is the normal dominant mammalian thymic ligand and is often more potent. | Functional in-vivo mouse evidence establishes biochemical capability; physiological DLL1 use in the normal human thymus remains less certain. |
| Hematopoietic lineage decisions | DLL1-mediated Notch signaling biases lymphoid progenitors away from B-cell development and can support T-lineage differentiation; ligand potency depends on receptor context, surface density, glycosylation, and extracellular-domain architecture. | Ectopic DLL1 reduced **B220-positive/CD19-positive** B-lineage cells. DLL1 induced T-lineage differentiation in stromal co-culture but was approximately **3–6-fold less efficient than DLL4** in the reported system. Its activity involves NOTCH1 and NOTCH2 and a DSL plus DOS-containing EGF1–2 interaction module. (hirano2020deltalike1and pages 9-11, hirano2020deltalike1and pages 2-3, hirano2020deltalike1and pages 6-7) | Suppression of B-cell fate and promotion of T-lineage programs under suitable experimental conditions; DLL1 is also required for aspects of marginal-zone B-cell homeostasis. | Mixed in-vivo and ex-vivo mouse evidence; ligand- and niche-specific outcomes caution against treating DLL1 and DLL4 as interchangeable. |
| DLL1-related neurodevelopmental disease | Heterozygous loss-of-function or haploinsufficiency reduces DLL1-dependent cell–cell signaling during brain development; the resulting phenotype is variable and may overlap broader 6q deletion syndromes. | Reported associations include developmental delay, cortical dysplasia, small cerebellum, hypotonia, ataxia, autistic features, hearing loss, and variably kyphosis or scoliosis. (umair2022clinicalgeneticsof pages 5-7, umair2022clinicalgeneticsof pages 7-8, umair2022clinicalgeneticsof pages 2-3) | Variable neurodevelopmental disorder with brain abnormalities; skeletal, sensory, cardiac, or craniofacial findings may accompany some variants but are not uniformly present. | Human genetic evidence exists, but genotype–phenotype correlations remain limited and heterogeneous. |
| Congenital vertebral malformation / spondylocostal dysostosis type 7 | Biallelic DLL1 dysfunction perturbs the Notch segmentation clock and somite boundary formation, providing a direct mechanistic link from impaired ligand function to vertebral segmentation defects. | A homozygous DLL1 missense variant, **c.1534G>A (p.Gly512Arg)**, was reported with scoliosis, multiple vertebral deformities, and thoracic vertebral fusions involving **T4–T5, T6–T8, and T11–T12**. The condition has been designated **autosomal-recessive SCDO7**, although only one DLL1 variant had been specifically linked to this phenotype in the 2022 review. (umair2022clinicalgeneticsof pages 7-8, umair2022clinicalgeneticsof pages 2-3, umair2022clinicalgeneticsof pages 3-4) | Congenital abnormal vertebral segmentation, scoliosis/kyphosis, and fused thoracic vertebrae; neurological features may coexist in reported DLL1 disease. | Rare human genetic evidence; the DLL1–SCDO7 relationship is biologically compelling but based on very few families, so prevalence and phenotypic range are uncertain. |
| Cancer biology | DLL1 activates canonical Notch signaling, but the result is tumor- and cell-context dependent. It has been associated with tumor-cell survival or proliferation in glioma and estrogen-dependent signaling in luminal breast cancer, while other studies suggest tumor-suppressive or immune-stimulatory effects in osteosarcoma, pancreatic carcinoma, and lung cancer. | In osteosarcoma, miR-34a-5p-associated DLL1 downregulation was linked to multidrug chemoresistance. Engineered multivalent DLL1 enhanced antitumor T-cell immunity and improved EGFR-targeted treatment in lung-cancer models. (you2023targetingthedllnotch pages 8-8, you2023targetingthedllnotch pages 8-9, you2023targetingthedllnotch pages 4-5) | Depending on context, altered DLL1 may promote growth and survival, contribute to drug resistance, or be exploited to strengthen antitumor immunity. | Predominantly preclinical and correlative evidence; no established DLL1-specific approved cancer therapy, and effects of broad Notch inhibition cannot be attributed automatically to DLL1. |
| Biomarker and translational application in infection/sepsis | Activated human monocytes increase surface DLL1, and a soluble form is detectable in plasma; elevated soluble DLL1 may reflect infection-driven immune activation and Notch-pathway engagement. | A 2023 secondary analysis evaluated **405 patients**. For recognizing sepsis, soluble DLL1 achieved **AUROC 0.823 (95% CI 0.731–0.914)** versus CRP **0.758**, procalcitonin **0.593**, and white-cell count **0.577**. (vazquezulloa2022reversibleandbidirectional pages 13-14) | Soluble DLL1 distinguished sepsis from uncomplicated infection and sterile inflammation in the analyzed cohorts, supporting investigation as a diagnostic biomarker. | Promising clinical observational evidence, but external prospective validation and assay standardization are required before routine implementation. |


*Table: This table integrates mechanistic, phenotypic, and translational evidence for DLL1 across developmental timing, stem-cell regulation, immunity, inherited disease, cancer, and sepsis. It distinguishes strong functional evidence from context-dependent or still-preclinical applications.*

## Conclusions

DLL1 (Delta-like protein 1) is a canonical type I transmembrane Notch ligand that mediates juxtacrine cell-cell communication through force-dependent receptor activation (sen2023theintricatenotch pages 2-4, stojanovic2024tolllikereceptorsas pages 1-2, hirano2020deltalike1and pages 1-2). Its primary molecular function is to bind NOTCH1 and NOTCH2 receptors on adjacent cells via its DSL domain and DOS-containing EGF repeats, triggering proteolytic release of NICD and activation of HES/HEY family transcriptional programs (sen2023theintricatenotch pages 2-4, hirano2022dll1canfunction pages 4-6, katoh2020precisionmedicinefor pages 1-2). DLL1 localizes to the plasma membrane, particularly at adherens junctions, where it is regulated by ubiquitination, endocytosis, and PDZ-scaffold interactions (vazquezulloa2022reversibleandbidirectional pages 15-16, vazquezulloa2022reversibleandbidirectional pages 11-13).

Functionally, DLL1 plays critical roles in: (1) somitogenesis, where its oscillatory expression synchronizes the segmentation clock that patterns the vertebral axis (miao2024cellularandmolecular pages 4-6, ramesh2024speciesspecificrolesof pages 13-14); (2) muscle stem-cell maintenance, where oscillatory DLL1 balances differentiation and self-renewal during regeneration (zhang2021oscillationsofdeltalike1 pages 1-2, zhang2021oscillationsofdeltalike1 pages 4-5); (3) T-cell development and hematopoietic lineage specification (hirano2022dll1canfunction pages 4-6, hirano2022dll1canfunction pages 1-2, hirano2020deltalike1and pages 2-3); and (4) additional developmental processes including neural differentiation via lateral inhibition (sachan2023notchsignallingmultifaceted pages 4-4).

Clinically, DLL1 mutations cause spondylocostal dysostosis type 7 and neurodevelopmental disorders (umair2022clinicalgeneticsof pages 7-8, umair2022clinicalgeneticsof pages 2-3), while altered DLL1 expression is associated with context-dependent roles in cancer, chemoresistance, and potential immunotherapy applications (you2023targetingthedllnotch pages 8-8, you2023targetingthedllnotch pages 8-9). Soluble DLL1 shows promise as a sepsis biomarker (vazquezulloa2022reversibleandbidirectional pages 13-14). The evidence base for DLL1 function is strong, with recent authoritative reviews (2023–2024) and mechanistic studies providing comprehensive molecular, developmental, and translational insights (sen2023theintricatenotch pages 2-4, miao2024cellularandmolecular pages 4-6, ramesh2024speciesspecificrolesof pages 13-14, zhang2021oscillationsofdeltalike1 pages 1-2).

**Key References:**
- Sen & Ghosh (2023): Comprehensive review of Notch signaling dynamics in cancer therapeutics (sen2023theintricatenotch pages 2-4)
- Hirano et al. (2020): Definitive structure-function analysis of DLL1 versus DLL4 extracellular domains (hirano2020deltalike1and pages 1-2, hirano2020deltalike1and pages 3-4)
- Zhang et al. (2021): Landmark study on DLL1 oscillations in muscle stem cells (zhang2021oscillationsofdeltalike1 pages 4-5, zhang2021oscillationsofdeltalike1 pages 1-2)
- Miao & Pourquié (2024): Authoritative review of vertebrate somitogenesis including DLL1 segmentation-clock function (miao2024cellularandmolecular pages 4-6)
- Umair et al. (2022): Clinical genetics of spondylocostal dysostosis including DLL1-associated SCDO7 (umair2022clinicalgeneticsof pages 7-8, umair2022clinicalgeneticsof pages 2-3)

References

1. (sen2023theintricatenotch pages 2-4): Plaboni Sen and Siddhartha Sankar Ghosh. The intricate notch signaling dynamics in therapeutic realms of cancer. ACS pharmacology & translational science, 6 5:651-670, May 2023. URL: https://doi.org/10.1021/acsptsci.2c00239, doi:10.1021/acsptsci.2c00239. This article has 26 citations and is from a peer-reviewed journal.

2. (hirano2020deltalike1and pages 1-2): Ken-ichi Hirano, Akiko Suganami, Yutaka Tamura, Hideo Yagita, Sonoko Habu, Motoo Kitagawa, Takehito Sato, and Katsuto Hozumi. Delta-like 1 and delta-like 4 differently require their extracellular domains for triggering notch signaling in mice. Jan 2020. URL: https://doi.org/10.7554/elife.50979, doi:10.7554/elife.50979. This article has 19 citations and is from a domain leading peer-reviewed journal.

3. (stojanovic2024tolllikereceptorsas pages 1-2): Mario Stojanovic and Svjetlana Kalanj-Bognar. Toll-like receptors as a missing link in notch signaling cascade during neurodevelopment. Frontiers in Molecular Neuroscience, Nov 2024. URL: https://doi.org/10.3389/fnmol.2024.1465023, doi:10.3389/fnmol.2024.1465023. This article has 3 citations.

4. (hirano2020deltalike1and pages 3-4): Ken-ichi Hirano, Akiko Suganami, Yutaka Tamura, Hideo Yagita, Sonoko Habu, Motoo Kitagawa, Takehito Sato, and Katsuto Hozumi. Delta-like 1 and delta-like 4 differently require their extracellular domains for triggering notch signaling in mice. Jan 2020. URL: https://doi.org/10.7554/elife.50979, doi:10.7554/elife.50979. This article has 19 citations and is from a domain leading peer-reviewed journal.

5. (hirano2020deltalike1and pages 7-8): Ken-ichi Hirano, Akiko Suganami, Yutaka Tamura, Hideo Yagita, Sonoko Habu, Motoo Kitagawa, Takehito Sato, and Katsuto Hozumi. Delta-like 1 and delta-like 4 differently require their extracellular domains for triggering notch signaling in mice. Jan 2020. URL: https://doi.org/10.7554/elife.50979, doi:10.7554/elife.50979. This article has 19 citations and is from a domain leading peer-reviewed journal.

6. (vazquezulloa2022reversibleandbidirectional pages 8-11): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.

7. (hirano2020deltalike1and pages 8-9): Ken-ichi Hirano, Akiko Suganami, Yutaka Tamura, Hideo Yagita, Sonoko Habu, Motoo Kitagawa, Takehito Sato, and Katsuto Hozumi. Delta-like 1 and delta-like 4 differently require their extracellular domains for triggering notch signaling in mice. Jan 2020. URL: https://doi.org/10.7554/elife.50979, doi:10.7554/elife.50979. This article has 19 citations and is from a domain leading peer-reviewed journal.

8. (hirano2020deltalike1and pages 6-7): Ken-ichi Hirano, Akiko Suganami, Yutaka Tamura, Hideo Yagita, Sonoko Habu, Motoo Kitagawa, Takehito Sato, and Katsuto Hozumi. Delta-like 1 and delta-like 4 differently require their extracellular domains for triggering notch signaling in mice. Jan 2020. URL: https://doi.org/10.7554/elife.50979, doi:10.7554/elife.50979. This article has 19 citations and is from a domain leading peer-reviewed journal.

9. (hirano2022dll1canfunction pages 4-6): Ken-ichi Hirano, Hiroyuki Hosokawa, Takashi Yahata, Kiyoshi Ando, Masayuki Tanaka, Jin Imai, Masaki Yazawa, Masato Ohtsuka, Naoko Negishi, Sonoko Habu, Takehito Sato, and Katsuto Hozumi. Dll1 can function as a ligand of notch1 and notch2 in the thymic epithelium. Frontiers in Immunology, Mar 2022. URL: https://doi.org/10.3389/fimmu.2022.852427, doi:10.3389/fimmu.2022.852427. This article has 9 citations and is from a peer-reviewed journal.

10. (hirano2020deltalike1and pages 9-11): Ken-ichi Hirano, Akiko Suganami, Yutaka Tamura, Hideo Yagita, Sonoko Habu, Motoo Kitagawa, Takehito Sato, and Katsuto Hozumi. Delta-like 1 and delta-like 4 differently require their extracellular domains for triggering notch signaling in mice. Jan 2020. URL: https://doi.org/10.7554/elife.50979, doi:10.7554/elife.50979. This article has 19 citations and is from a domain leading peer-reviewed journal.

11. (vazquezulloa2022reversibleandbidirectional pages 11-13): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.

12. (hirano2022dll1canfunction pages 1-2): Ken-ichi Hirano, Hiroyuki Hosokawa, Takashi Yahata, Kiyoshi Ando, Masayuki Tanaka, Jin Imai, Masaki Yazawa, Masato Ohtsuka, Naoko Negishi, Sonoko Habu, Takehito Sato, and Katsuto Hozumi. Dll1 can function as a ligand of notch1 and notch2 in the thymic epithelium. Frontiers in Immunology, Mar 2022. URL: https://doi.org/10.3389/fimmu.2022.852427, doi:10.3389/fimmu.2022.852427. This article has 9 citations and is from a peer-reviewed journal.

13. (kulkarni2024noncanonicalnongenomicmorphogen pages 3-5): Paresh P. Kulkarni, Mohammad Ekhlak, and Debabrata Dash. Non-canonical non-genomic morphogen signaling in anucleate platelets: a critical determinant of prothrombotic function in circulation. Cell Communication and Signaling : CCS, Jan 2024. URL: https://doi.org/10.1186/s12964-023-01448-y, doi:10.1186/s12964-023-01448-y. This article has 6 citations.

14. (nian2022evolvingrolesof pages 7-9): Fang-Shin Nian and Pei-Shan Hou. Evolving roles of notch signaling in cortical development. Frontiers in Neuroscience, Mar 2022. URL: https://doi.org/10.3389/fnins.2022.844410, doi:10.3389/fnins.2022.844410. This article has 35 citations and is from a peer-reviewed journal.

15. (vazquezulloa2022reversibleandbidirectional pages 15-16): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.

16. (vazquezulloa2022reversibleandbidirectional pages 13-14): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.

17. (vazquezulloa2022reversibleandbidirectional pages 5-7): Elenaé Vázquez-Ulloa, Kai-Lan Lin, Marcela Lizano, and Cecilia Sahlgren. Reversible and bidirectional signaling of notch ligands. Critical Reviews in Biochemistry and Molecular Biology, 57:377-398, Jul 2022. URL: https://doi.org/10.1080/10409238.2022.2113029, doi:10.1080/10409238.2022.2113029. This article has 29 citations and is from a peer-reviewed journal.

18. (katoh2020precisionmedicinefor pages 1-2): Masuko Katoh and Masaru Katoh. Precision medicine for human cancers with notch signaling dysregulation (review). International Journal of Molecular Medicine, 45:279-297, Dec 2020. URL: https://doi.org/10.3892/ijmm.2019.4418, doi:10.3892/ijmm.2019.4418. This article has 265 citations and is from a peer-reviewed journal.

19. (mcintyre2020overviewofbasic pages 25-27): Brendan McIntyre, Takayuki Asahara, and Cantas Alev. Overview of basic mechanisms of notch signaling in development and disease. Advances in experimental medicine and biology, 1227:9-27, Jan 2020. URL: https://doi.org/10.1007/978-3-030-36422-9\_2, doi:10.1007/978-3-030-36422-9\_2. This article has 42 citations and is from a peer-reviewed journal.

20. (miao2024cellularandmolecular pages 4-6): Yuchuan Miao and Olivier Pourquié. Cellular and molecular control of vertebrate somitogenesis. Nature reviews. Molecular cell biology, 25:517-533, Feb 2024. URL: https://doi.org/10.1038/s41580-024-00709-z, doi:10.1038/s41580-024-00709-z. This article has 63 citations.

21. (ramesh2024speciesspecificrolesof pages 13-14): Pranav S. Ramesh and Li-Fang Chu. Species-specific roles of the notch ligands, receptors, and targets orchestrating the signaling landscape of the segmentation clock. Frontiers in Cell and Developmental Biology, Jan 2024. URL: https://doi.org/10.3389/fcell.2023.1327227, doi:10.3389/fcell.2023.1327227. This article has 14 citations.

22. (anderson2020fgf4iscritical pages 1-5): Matthew J. Anderson, Valentin Magidson, Ryoichiro Kageyama, and Mark Lewandoski. Fgf4 is critical for maintaining hes7 levels and notch oscillations in the somite segmentation clock. bioRxiv, Feb 2020. URL: https://doi.org/10.1101/2020.02.12.945931, doi:10.1101/2020.02.12.945931. This article has 4 citations.

23. (ramesh2024speciesspecificrolesof pages 14-16): Pranav S. Ramesh and Li-Fang Chu. Species-specific roles of the notch ligands, receptors, and targets orchestrating the signaling landscape of the segmentation clock. Frontiers in Cell and Developmental Biology, Jan 2024. URL: https://doi.org/10.3389/fcell.2023.1327227, doi:10.3389/fcell.2023.1327227. This article has 14 citations.

24. (zhang2021oscillationsofdeltalike1 pages 4-5): Yao Zhang, Ines Lahmann, Katharina Baum, Hiromi Shimojo, Philippos Mourikis, Jana Wolf, Ryoichiro Kageyama, and Carmen Birchmeier. Oscillations of delta-like1 regulate the balance between differentiation and maintenance of muscle stem cells. Nature Communications, Feb 2021. URL: https://doi.org/10.1038/s41467-021-21631-4, doi:10.1038/s41467-021-21631-4. This article has 98 citations and is from a highest quality peer-reviewed journal.

25. (zhang2021oscillationsofdeltalike1 pages 1-2): Yao Zhang, Ines Lahmann, Katharina Baum, Hiromi Shimojo, Philippos Mourikis, Jana Wolf, Ryoichiro Kageyama, and Carmen Birchmeier. Oscillations of delta-like1 regulate the balance between differentiation and maintenance of muscle stem cells. Nature Communications, Feb 2021. URL: https://doi.org/10.1038/s41467-021-21631-4, doi:10.1038/s41467-021-21631-4. This article has 98 citations and is from a highest quality peer-reviewed journal.

26. (sachan2023notchsignallingmultifaceted pages 14-14): Nalani Sachan, Vartika Sharma, Mousumi Mutsuddi, and Ashim Mukherjee. Notch signalling: multifaceted role in development and disease. The FEBS Journal, 291:3030-3059, May 2024. URL: https://doi.org/10.1111/febs.16815, doi:10.1111/febs.16815. This article has 124 citations.

27. (zhang2021oscillationsofdeltalike1 pages 3-4): Yao Zhang, Ines Lahmann, Katharina Baum, Hiromi Shimojo, Philippos Mourikis, Jana Wolf, Ryoichiro Kageyama, and Carmen Birchmeier. Oscillations of delta-like1 regulate the balance between differentiation and maintenance of muscle stem cells. Nature Communications, Feb 2021. URL: https://doi.org/10.1038/s41467-021-21631-4, doi:10.1038/s41467-021-21631-4. This article has 98 citations and is from a highest quality peer-reviewed journal.

28. (hirano2020deltalike1and pages 2-3): Ken-ichi Hirano, Akiko Suganami, Yutaka Tamura, Hideo Yagita, Sonoko Habu, Motoo Kitagawa, Takehito Sato, and Katsuto Hozumi. Delta-like 1 and delta-like 4 differently require their extracellular domains for triggering notch signaling in mice. Jan 2020. URL: https://doi.org/10.7554/elife.50979, doi:10.7554/elife.50979. This article has 19 citations and is from a domain leading peer-reviewed journal.

29. (hirano2020deltalike1and pages 17-18): Ken-ichi Hirano, Akiko Suganami, Yutaka Tamura, Hideo Yagita, Sonoko Habu, Motoo Kitagawa, Takehito Sato, and Katsuto Hozumi. Delta-like 1 and delta-like 4 differently require their extracellular domains for triggering notch signaling in mice. Jan 2020. URL: https://doi.org/10.7554/elife.50979, doi:10.7554/elife.50979. This article has 19 citations and is from a domain leading peer-reviewed journal.

30. (umair2022clinicalgeneticsof pages 7-8): Muhammad Umair, Muhammad Younus, Sarfraz Shafiq, Anam Nayab, and Majid Alfadhel. Clinical genetics of spondylocostal dysostosis: a mini review. Frontiers in Genetics, Nov 2022. URL: https://doi.org/10.3389/fgene.2022.996364, doi:10.3389/fgene.2022.996364. This article has 24 citations and is from a peer-reviewed journal.

31. (umair2022clinicalgeneticsof pages 2-3): Muhammad Umair, Muhammad Younus, Sarfraz Shafiq, Anam Nayab, and Majid Alfadhel. Clinical genetics of spondylocostal dysostosis: a mini review. Frontiers in Genetics, Nov 2022. URL: https://doi.org/10.3389/fgene.2022.996364, doi:10.3389/fgene.2022.996364. This article has 24 citations and is from a peer-reviewed journal.

32. (umair2022clinicalgeneticsof pages 3-4): Muhammad Umair, Muhammad Younus, Sarfraz Shafiq, Anam Nayab, and Majid Alfadhel. Clinical genetics of spondylocostal dysostosis: a mini review. Frontiers in Genetics, Nov 2022. URL: https://doi.org/10.3389/fgene.2022.996364, doi:10.3389/fgene.2022.996364. This article has 24 citations and is from a peer-reviewed journal.

33. (umair2022clinicalgeneticsof pages 8-10): Muhammad Umair, Muhammad Younus, Sarfraz Shafiq, Anam Nayab, and Majid Alfadhel. Clinical genetics of spondylocostal dysostosis: a mini review. Frontiers in Genetics, Nov 2022. URL: https://doi.org/10.3389/fgene.2022.996364, doi:10.3389/fgene.2022.996364. This article has 24 citations and is from a peer-reviewed journal.

34. (umair2022clinicalgeneticsof pages 5-7): Muhammad Umair, Muhammad Younus, Sarfraz Shafiq, Anam Nayab, and Majid Alfadhel. Clinical genetics of spondylocostal dysostosis: a mini review. Frontiers in Genetics, Nov 2022. URL: https://doi.org/10.3389/fgene.2022.996364, doi:10.3389/fgene.2022.996364. This article has 24 citations and is from a peer-reviewed journal.

35. (you2023targetingthedllnotch pages 4-5): Weon-Kyoo You, Thomas J. Schuetz, and Sang Hoon Lee. Targeting the dll/notch signaling pathway in cancer: challenges and advances in clinical development. Molecular Cancer Therapeutics, 22:3-11, Oct 2023. URL: https://doi.org/10.1158/1535-7163.mct-22-0243, doi:10.1158/1535-7163.mct-22-0243. This article has 86 citations and is from a peer-reviewed journal.

36. (you2023targetingthedllnotch pages 8-9): Weon-Kyoo You, Thomas J. Schuetz, and Sang Hoon Lee. Targeting the dll/notch signaling pathway in cancer: challenges and advances in clinical development. Molecular Cancer Therapeutics, 22:3-11, Oct 2023. URL: https://doi.org/10.1158/1535-7163.mct-22-0243, doi:10.1158/1535-7163.mct-22-0243. This article has 86 citations and is from a peer-reviewed journal.

37. (you2023targetingthedllnotch pages 8-8): Weon-Kyoo You, Thomas J. Schuetz, and Sang Hoon Lee. Targeting the dll/notch signaling pathway in cancer: challenges and advances in clinical development. Molecular Cancer Therapeutics, 22:3-11, Oct 2023. URL: https://doi.org/10.1158/1535-7163.mct-22-0243, doi:10.1158/1535-7163.mct-22-0243. This article has 86 citations and is from a peer-reviewed journal.

38. (you2023targetingthedllnotch pages 1-1): Weon-Kyoo You, Thomas J. Schuetz, and Sang Hoon Lee. Targeting the dll/notch signaling pathway in cancer: challenges and advances in clinical development. Molecular Cancer Therapeutics, 22:3-11, Oct 2023. URL: https://doi.org/10.1158/1535-7163.mct-22-0243, doi:10.1158/1535-7163.mct-22-0243. This article has 86 citations and is from a peer-reviewed journal.

39. (you2023targetingthedllnotch pages 2-3): Weon-Kyoo You, Thomas J. Schuetz, and Sang Hoon Lee. Targeting the dll/notch signaling pathway in cancer: challenges and advances in clinical development. Molecular Cancer Therapeutics, 22:3-11, Oct 2023. URL: https://doi.org/10.1158/1535-7163.mct-22-0243, doi:10.1158/1535-7163.mct-22-0243. This article has 86 citations and is from a peer-reviewed journal.

40. (hirano2020deltalike1and pages 11-13): Ken-ichi Hirano, Akiko Suganami, Yutaka Tamura, Hideo Yagita, Sonoko Habu, Motoo Kitagawa, Takehito Sato, and Katsuto Hozumi. Delta-like 1 and delta-like 4 differently require their extracellular domains for triggering notch signaling in mice. Jan 2020. URL: https://doi.org/10.7554/elife.50979, doi:10.7554/elife.50979. This article has 19 citations and is from a domain leading peer-reviewed journal.

41. (zhang2021oscillationsofdeltalike1 pages 12-13): Yao Zhang, Ines Lahmann, Katharina Baum, Hiromi Shimojo, Philippos Mourikis, Jana Wolf, Ryoichiro Kageyama, and Carmen Birchmeier. Oscillations of delta-like1 regulate the balance between differentiation and maintenance of muscle stem cells. Nature Communications, Feb 2021. URL: https://doi.org/10.1038/s41467-021-21631-4, doi:10.1038/s41467-021-21631-4. This article has 98 citations and is from a highest quality peer-reviewed journal.

42. (sachan2023notchsignallingmultifaceted pages 4-4): Nalani Sachan, Vartika Sharma, Mousumi Mutsuddi, and Ashim Mukherjee. Notch signalling: multifaceted role in development and disease. The FEBS Journal, 291:3030-3059, May 2024. URL: https://doi.org/10.1111/febs.16815, doi:10.1111/febs.16815. This article has 124 citations.

## Artifacts

- [Edison artifact artifact-00](DLL1-deep-research-falcon_artifacts/artifact-00.md)
- [Edison artifact artifact-01](DLL1-deep-research-falcon_artifacts/artifact-01.md)

## Citations

1. sen2023theintricatenotch pages 2-4
2. stojanovic2024tolllikereceptorsas pages 1-2
3. vazquezulloa2022reversibleandbidirectional pages 15-16
4. vazquezulloa2022reversibleandbidirectional pages 11-13
5. vazquezulloa2022reversibleandbidirectional pages 13-14
6. katoh2020precisionmedicinefor pages 1-2
7. miao2024cellularandmolecular pages 4-6
8. ramesh2024speciesspecificrolesof pages 14-16
9. ramesh2024speciesspecificrolesof pages 13-14
10. umair2022clinicalgeneticsof pages 7-8
11. umair2022clinicalgeneticsof pages 5-7
12. you2023targetingthedllnotch pages 8-9
13. you2023targetingthedllnotch pages 8-8
14. you2023targetingthedllnotch pages 4-5
15. sachan2023notchsignallingmultifaceted pages 4-4
16. vazquezulloa2022reversibleandbidirectional pages 8-11
17. kulkarni2024noncanonicalnongenomicmorphogen pages 3-5
18. nian2022evolvingrolesof pages 7-9
19. vazquezulloa2022reversibleandbidirectional pages 5-7
20. mcintyre2020overviewofbasic pages 25-27
21. sachan2023notchsignallingmultifaceted pages 14-14
22. umair2022clinicalgeneticsof pages 2-3
23. umair2022clinicalgeneticsof pages 3-4
24. umair2022clinicalgeneticsof pages 8-10
25. you2023targetingthedllnotch pages 1-1
26. you2023targetingthedllnotch pages 2-3
27. https://doi.org/10.1021/acsptsci.2c00239,
28. https://doi.org/10.7554/elife.50979,
29. https://doi.org/10.3389/fnmol.2024.1465023,
30. https://doi.org/10.1080/10409238.2022.2113029,
31. https://doi.org/10.3389/fimmu.2022.852427,
32. https://doi.org/10.1186/s12964-023-01448-y,
33. https://doi.org/10.3389/fnins.2022.844410,
34. https://doi.org/10.3892/ijmm.2019.4418,
35. https://doi.org/10.1007/978-3-030-36422-9\_2,
36. https://doi.org/10.1038/s41580-024-00709-z,
37. https://doi.org/10.3389/fcell.2023.1327227,
38. https://doi.org/10.1101/2020.02.12.945931,
39. https://doi.org/10.1038/s41467-021-21631-4,
40. https://doi.org/10.1111/febs.16815,
41. https://doi.org/10.3389/fgene.2022.996364,
42. https://doi.org/10.1158/1535-7163.mct-22-0243,